The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of an oral study drug for atopic dermatitis (eczema). This study will compare different release forms of the study drug when taken with or without food
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin conditions. It causes a rash and itching and can negatively affect patients’ emotional well-being. There is no cure for AD and while available treatments may provide symptom relief, the community needs new long-term treatment options.
Learn how you can support patients as a healthy volunteer below.
Who may participate
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. Healthy volunteers are a vital part of medical discovery and help build the foundations for further research.
In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
**females must be unable to bear children
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18+ years
Sex
All sexes
Referral bonus
Up to $250
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 16 consecutive overnights. Starting the morning after your admission, you will receive single oral doses of the study drug up to 5 times during your stay, each one at least 3 days apart. There are 3 different release formulations of the study drug used in this study. You will receive each formulation at least once, but the order in which you receive them will be chosen at random. All doses will be provided as tablets to swallow and may be given with or without food.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
Required overnight stays
16 consecutive overnights
Long-term follow up
1 phone call
How long is this study?
About 42 days
Compensation
Up to $7,300 upon completion of the study
The PCRU Loyalty Program has arrived!
Our new Loyalty Program offers unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.